Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Aspart 30 Injection plus Metformin in Type 2 Diabetes Mellitus
CTR20190121Phase 3Completed
- Sponsor
- Jilin Jinsheng Pharmaceutical
- Start
- Feb 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of insulin aspart in type 2 diabetes mellitus (T2DM), sponsored by Jilin Jinsheng Pharmaceutical. Started Feb 2019; status: completed.
02
Drugs
insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20190121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190121.